Objectives The chronic and progressive nature of diabetes is usually associated with micro-and macrovascular complications where failure of pancreatic b-cell function and a general condition of hyperglycaemia is created. One possible factor is failure of the patient to comply with and adhere to the prescribed insulin due to the inconvenient administration route. This review summarizes the rationale for oral insulin administration, existing barriers and some counter-strategies trialled. Key findings Oral insulin mimics the physiology of endogenous insulin secreted by pancreas. Following the intestinal absorption of oral insulin, it reaches the liver at high concentration via the portal vein. Oral insulin on the other hand has the potential to protect pancreatic b-cells from autoimmune destruction. Structural modification, targeting a particular tissue/receptor, and the use of innovative pharmaceutical formulations such as nanoparticles represent strategies introduced to improve oral insulin bioavailability. They showed promising results in overcoming the hurdles facing oral insulin delivery, although delivery is far from ideal. Summary The use of advanced pharmaceutical technologies and further research in particulate carrier system delivery predominantly nanoparticle utilization would offer useful tools in delivering insulin via the oral route which in turn would potentially improve diabetic patient compliance to insulin and the overall management of diabetes.
Introduction
Insulin is administered to diabetic patients through the parenteral route. Most protein drugs are administered by injection due to their perceived low bioavailability if delivered by other routes. Insulin is injected subcutaneously, and this is usually associated with pain, trauma, distress, leading to poor patient compliance [1, 2] which in turn cascades into a chain of undesired effects. The exogenous insulin is significantly able to reduce the rate of morbidity and mortality, although around 60% of diabetic patients fail to achieve long-term normoglycaemia, [3] presumably because of non-compliance issues resulting from needle phobia and complexity of the insulin treatment regimen. In effect, poor patient compliance would contribute to long-term poor glycaemic control and diabetic ketoacidosis and spark a series of macro-and microvascular complications. [4] Oral insulin was first trialled in 1922 with poor results. [5] Even to this day, a successful oral insulin preparation has been elusive, but is expected to dramatically improve patient outcomes. This review will address and discuss the following topics: insulin-related physiology and rationale for oral insulin use, basic challenges in oral delivery of insulin, some strategies trialled and finally mitogenic concerns of oral insulin.
Insulin-related physiology
After it is secreted from pancreatic b-cells into the portal vein, insulin is directly transferred to the liver where it is subjected to the hepatic first-pass effect where almost half of the polypeptide hormone experiences hepatic degradation. [6] Such an environment creates an insulin concentration gradient between hepatic portal and systemic circulation, where the liver is exposed to insulin concentration twofold to fourfold higher than that observed in the peripheral systemic circulation. [6] Available insulin preparations fail to mimic the endogenous insulin pathway where the injectable insulin analogues are delivered directly to the peripheral circulation, hence reversing the insulin concentration gradient in normal physiology, and as a result, insulin reaches the liver at much lower concentrations than those in non-diabetic individuals. [7] Diabetic patients treated with injectable insulin preparations are subjected to the side-effects of hyperinsulinaemia, weight gain and hypoglycaemic risks. [7] A step towards normal physiology
The long-term use of the conventional insulin preparations, collectively called multiple daily insulin (MDI), results in poor glycemic control, risks of hypoglycaemia and needle phobia. [8, 9] On the other hand, treating the dawn phenomenon (early morning hyperglycaemia especially in pregnant patients) with conventional insulin preparations is quite complex and troublesome. [8, 9] The aforementioned drawbacks raised the desire of diabetologists to get the basal insulin at a more physiological level through delivering predetermined continuous subcutaneous insulin infusion (CSII) or insulin pump which can also get programmed to deliver postprandial bolus insulin if required. [8, 9] In the late 1970s, insulin pumps were introduced and it was initially thought to be the most physiological way of delivering insulin subcutaneously to achieve near-normoglycaemia.
CSII offered more flexibility in daily life and that is probably why they were recommended during pregnancy or for preconception care and for type 1 diabetic children and adolescents. [8, 9] New model insulin infusion pumps are light in weight (less than 0.5 kg), small in size, and contain replaceable insulin syringes or cartridges. The insulin is infused from the pump to the subcutaneous tissue through a simple and manually inserted catheter. [8] 
Less invasive insulin delivery
Despite all the initial excitement, delivery of insulin through MDI or CSII still did not mimic the physiology of the endogenously secreted human insulin, where the insulin is reversely distributed between portal and systemic circulation which has driven researchers to develop less invasive and more physiological routes of insulin administration such as transdermal, inhaled, nasal, buccal, ocular, rectal and the highly preferred oral insulin. [7] While stability requirements for formulation of a protein hormone as well as making sure of its therapeutic efficacy were taken into consideration by researchers, most of the developed formulations have failed to demonstrate satisfying bioavailability results. [7, 10] Oral insulin and rationale for its use
Physiological rationale
Orally administered insulin better replicates the normal physiological insulin pathway and leads to better glucose homeostasis. [11, 12] After its absorption from the intestinal lumen, insulin is transported via the portal circulation to the liver (the ultimate target) [13] creating a high porto-systemic gradient. The oral route offers decreased levels of systemic insulin, [14] hence less hypoglycaemic episodes and weight gain problems (Figure 1) .
The liver on the other hand is highly sensitive to insulin, and within few minutes, glucose production by the liver is blocked by a portal insulin concentration of 50 lu/ml in healthy objects and by around 100 lu/ml in diabetic patients. [15] [16] [17] Interestingly, oral insulin plays a significant role in protection of b-cells of the pancreas from autoimmune destruction. [18] Another study concluded the possibility of early insulin therapy to improve b-cell function and provided a chance for b-cell rest. [1, 19] Insulin administered orally theoretically should be able to overcome the slow first phase release kinetics encountered with subcutaneous administration. [1, 20] 
Pharmaceutical rationale
It has been suggested that oral insulin offers induction of oral tolerance or immune modulating effect which is likely to help in prevention of diabetes. [1, 21] The theory behind this phenomenon is that oral administration of a low dose of antigen alters responsiveness of systemic T cell to that antigen which seems to inhibit autoimmune diseases such as type 1 diabetes. [21] This effect has been experimented upon non-obese diabetic (NOD) mice treated with oral insulin, where peripheral T cells do not migrate to pancreatic islets [21] which might explain prevention of type 1 diabetes in NOD mice. [21] Despite its lower bioavailability, oral delivery of peptides showed high level of acceptance by patients with improved level of compliance [22] avoiding pain, discomfort, possible infections by injectable forms in addition to being less expensive. These are all factors that favour a switch to oral delivery of therapeutic peptides such as insulin. [22] Challenges in oral delivery of insulin
The fundamental barrier to the oral delivery of proteins is the gastrointestinal tract (GIT). The GIT functions as an absorptive and protective organ. Active macromolecules have to undergo degradation into inactive components before they face the next absorption barrier, the tight epithelium. These natural mechanisms thus also act as a defence shield against environmental pathogens.
[ [23] [24] [25] The epithelial cell layer comprises different types of cells ( Figure 2 ): A Enterocytes: The most abundant, with dense wellordered brush border, has absorptive function via transporting nutrients. [26, 27] B Goblet cells: The second most abundant in the epithelium which acts as a secretory reservoir of mucus. [26, 27] C Paneth cells, when exposed to bacteria, and antimicrobial proteins are secreted to kill the invading bacteria [26, 27] . D Microfold cells (M-cells) of Peyer's patch characterized by less cytoplasmic lysosomes and lack of a mucous layer covering their surface. M-cells take up antigens and microorganisms from the lumen of the intestine and present these to the immune system resident in the mucosa. [28, 29] (a) The tight junctions (TJs) between adjacent epithelial cells maintain the intactness of the intestinal epithelium structure. These TJs are composed of various transmembrane proteins such as claudins and occludins. [30, 31] Barriers to oral insulin Existing barriers could be categorized into three main subtypes, namely physical, biochemical and formulation-based. (Table 1 summarizes possible barriers for oral insulin delivery and some of the strategies used).
Physical barriers
1 The mucous layer: Mucus is the first barrier which functions as both diffusional and enzymatic barrier encountered by polypeptides. [32, 33] Mucus is continuously secreted and probably because of its negative charge, it filters out positively charged drugs and proteins by electrostatic interaction. [32] [33] [34] 2 Intestinal epithelium: The intestinal epithelium is composed of a single layer of columnar epithelial cells. [26] [27] [28] [29] Passive diffusion is limited to lipophilic drugs less than 700 Da in molecular weight, [35] and because the molecular weight of insulin is 5800 Da, [36] this renders transcellular passive diffusion of insulin into cells very difficult. 3 Tight junctions: This dynamic structure is selectively permeable to small hydrophilic molecules (nutrients, ions and certain drugs). [30, 31] Solutes of molecular radius more than 15 A are usually excluded from traversing this barrier. [31] Biochemical barriers 1 Luminal pH: pH varies from highly acidic (1.2-3.0) in the stomach to slightly basic (6.5-8.0) in the intestine. [37] Such pH variation can cause pH-induced oxidation and deamination of protein drugs. [38] 2 Enzymatic degradation: Proteolysis starts at the stomach through the action of pepsin and continues throughout the intestine due to chymotrypsin, elastase and carboxypeptidases. [39] Presystemic degradation of proteins could also be attributed to cytosolic and membranebound enzymes of the enterocytes. [39] Insulin is predominantly degraded by trypsin, a-chymotrypsin and carboxypeptidases in the mucous layer as well as intestinal lumen, with research also showing the existence of a specific insulin-degrading enzyme (IDE) on the brush-border membrane. [40, 41] Peptide drugs that do cross the intestinal epithelial barrier then undergo further degradation in the liver (hepatic first-pass metabolism). [1, 42] It has initially been thought that the inhibition of the IDE could be of value in preserving oral insulin formulations from enzymatic degradation, thereby improving its oral absorption and efficacy. A novel potent IDE inhibitor (6bK) has been revealed in a recent study which unfortunately did not improve oral insulin delivery. [43] IDE inhibition has been associated with increased amylin levels, which in turn slows the gastric emptying rate and improves glucose tolerance. [43] Thus, although the aim of improving oral insulin absorption was not attained, IDE inhibitors can still be of benefit in the treatment of T2DM patients. [43] 
Formulation barrier
The fabrication method could be the last barrier in formulation of peptide drugs. Being a sensitive polypeptide hormone and any conformational changes to insulin structure would affect its biological activity. [44] Better ways for formulation of oral peptide drugs have been tackled by many scientists through various approaches, with two foci being the overcoming of intestinal hurdles and the ensuing low bioavailability. [45, 46] Co-administration of enzyme inhibitors, addition of absorption enhancers or even slight modifications of the chemical structure of the protein are all among these techniques. [45, 46] These emerging techniques (below) are basically aiming to improve pharmacokinetic and pharmacodynamic characteristics of the hormone. [45] [46] [47] The suggested strategies trialled for oral insulin delivery can be classified into:
The covalent attachment of polyethylene glycol (PEG) to therapeutic peptides has been utilized previously; the technology is called PEGylation. [48] PEGylation has been used to decrease the rate of clearance and improve the pharmacological and biological properties of peptides and eliminates the immunogenicity, allergenicity and antigenicity of insulin if compared with unmodified subcutaneous insulin. [49] (PEG-INTRON â ) or PEG-modified a-interferon is an example of this technology which has been approved for hepatitis C treatment. [50] The NOBEX Corporation worked on the same principal to develop hexyl insulin mono-conjugate-2 (HIM2). A shortchain PEG is linked to a lipophilic alkyl group to produce an oligomer. The amphiphilic oligomer was used to modify recombinant human insulin through attachment to lysine at position 29 of the B-chain [51] ( Figure 3 ). HIM2 showed increased solubility, absorption, good stability against enzymatic degradation, although oral bioavailability was still~5% and clinical studies showed efficacy in both type I and type II diabetic patients. [52, 53] The research into PEGylated insulin technology has also been pursued by Biocon, a large Indian pharmaceutical company. Biocon took over NOBEX in 2005 and acquired the intellectual property of HIM2 where they developed the oral insulin candidate (IN-105) as a secondgeneration tablet. [54] [55] [56] IN-105 had an improved stability profile in GIT and enhanced absorption and in comparison with normal insulin, lower immunogenicity, lower mitogenicity and the same pharmacological action. [55] Another example of structural modification has been pioneered by Emisphere's Eligen TM . The technology comprises a reversible non-covalent interaction of insulin with low molecular weight carriers (200-400 Da). [45] These carrier molecules are organic/lipophilic in nature to improve the lipophilicity of insulin and facilitates passive transcellular diffusion without affecting cell membrane integrity or TJs. [45] Despite the relative fast absorption rate obtained from the pharmacokinetic data, Emisphere did not show a satisfactory bioavailability even in the presence of the large amount of carriers needed per dose. [45, 55, 57] 2 Targeting receptor/tissue a Receptor-mediated endocytosis: It is thought that exploiting endogenous cellular transport systems could increase uptake of some drugs. [45, 53] Cell membrane transporters have been utilized previously to transport relatively small therapeutics. Receptor-mediated endocytosis, on the other hand, offered better results in transport of macromolecules and proteins. [53] Lectins, transferrin, immunoglobulins, folate, cyanocobalamin (vitamin B12, vit B12), epidermal growth factor and intrinsic protein complex are among receptor-recognizable ligands that have been covalently attached to a peptide to improve both specificity and intracellular delivery. [45, 53] This principle has been adopted by Access Pharmaceuticals in development of CobOral TM , a peptide-loaded dextran nanoparticle coated with cobalamin. Likewise, Apollo Life has developed a carbohydrate-based nanoparticle coated with Vit B12 called Oradell TM [56] . Vit B12-coated dextran nanoparticles loaded with insulin showed significant prolonged hypoglycaemic effect in a STZ diabetic rat model. [58] b Cell-penetrating peptides (CPPs): CPPs is a relatively recent strategy in its early stage which has the potential for effective delivery of liposomes, nanoparticles, small molecules, as well as peptide drugs. [59] The technique is based upon using a class of short peptides such as penetratin, oligoarginine, transportan and HIV-1 transactivator of transcription (TAT). [60] No clear mechanism of translocation and internalization of their cargoes into the cytoplasm has emerged, although direct perturbation of the cell membrane, endocytosis or channel formation is possible mechanisms that have been hypothesized. [61] CPPs showed no toxicity or side-effects with in-vivo use and the transport of insulin/TAT conjugate across Caco-2 cells showed significant improvement. [53, 62] 3 Formulation/pharmaceutical technologiesThe use of these formulation technologies/strategies does not include physicochemical modification of the peptide to withstand gastric conditions. In fact, shielding insulin by encapsulation in an enteric-coated dosage form, coadministration with protease inhibitor or addition of permeation enhancers have been deployed with varying degrees of success. Detergents, fatty acids or bile acid salts are among the absorption enhancers used to facilitate the internalization of the hormone and overcoming the intestinal conditions to some extent. [44] [45] [46] 56] Examples of formulation-related technologies are as follows:
a Gut-associated lymphoid tissues: Gut-associated lymphoid tissues are best represented by Microfold cells (M-cells) of Peyer's patch. M-cells are responsible for antigen sampling and microparticulate uptake smaller than 10 lm. [63, 64] An uptake that has been used before for mucosal vaccine delivery through the peroral route. [63] Nanoparticles of chitosan showed a significant protection of encapsulated insulin against enzymatic degradation, and such nanoparticles were able to cross the epithelium through Peyer's patches. [65, 66] b Protease inhibitors: As insulin is degraded by trypsin, a-chymotrypsin and elastase, inhibition of the activity of these enzymes would decrease presystemic insulin degradation and improve its absorption. [46] Longterm use of these inhibitors is still an issue which could result in protein malabsorption due to disturbed protein digestion. Protease inhibitors could also be associated with systemic toxicity. [44] To this end, the enzyme inhibitory effect of Na-glycocholate, aprotinin, bacitracin, soya bean trypsin inhibitor and camostat mesilate has been compared. Co-administration of these agents with insulin directly into isolated intestines of normal rats resulted in improvement of the bioavailability of insulin. The effect was more predominant in the large intestine than the small intestine where Na-glycocholate, bacitracin and camostat mesilate showed better results. [67] Chicken ovomucoid (Ckovm) and duck ovomucoid (Dkovm) also showed protective effect against trypsin and a-chymotrypsin degradation of insulin. This study concluded that Ckovm inhibited trypsinmediated degradation at 1 : 1 ratio, while Dkovm showed 100% protection against trypsin and a-chymotrypsin for 60 min at 1 : 2 ratio of enzyme inhibitor. [68] c Absorption enhancers/permeation enhancers (PEs):
PEs are a group of agents that promote absorption of therapeutics through perturbing the cell membrane to improve transcellular transport or by selective action on TJs to enhance paracellular permeability. Decreasing mucous fluidity, change in membrane fluidity and leakage of proteins by opening TJs are possible mechanisms suggested for their action. [46, 69] However, the long-term use of PE is a controversial issue, as some researchers are concerned about toxic effects upon prolonged use. [46, 69] However, others argue that their use is by far the most advanced technology in oral peptide delivery. They reckon clinical studies showed good safety profile and achieved consistency of bioavailability for peptides less than 10k Da. [70] Bile salts, ethylene diamine tetraacetic acid, surfactants, fatty acids and zonula occludens toxin (ZOT) are examples of permeation enhancers commonly used to improve oral peptide bioavailability. [44, 46, 69] In-vivo results showed that ZOT increased insulin oral absorption 10-fold from rabbit ileum and jejunum and no effect was noticed in colon. [71] d Site-specific deliveryColon targeting has been interestingly used to deliver therapeutic peptides and non-peptides. Low level of luminal and brush-border proteases compared to duodenum and jejunum encouraged scientists to the use of colon targeting to circumvent harsh gastric conditions. [56] Insulin has been encapsulated by pH-sensitive materials to control its release and that showed improved oral bioavailability. Polyacrylic-coated gelatin capsules loaded with insulin have been studied in rats and showed significant drop in the blood glucose level compared to intraperitoneal injection. [72] An interesting colon-specific drug delivery system, CODES TM , is based on a core tablet coated with different polymeric layers. CODES showed sustained release of insulin in the colon of dogs. The formula incorporated the hormone with meglumine (a pH adjuster), citric acid (insulin solubilizer), Na-glycocholate (a permeation enhancer) along with polyethylene oxide. [73, 74] Capsulin TM , a product of diabetology, is an enteric-coated capsule loaded with dry powder mixture of insulin, permeation enhancer and solubilizer. The ingredients of the capsule are generally safe pharmacopoeial excipients. [75] [76] [77] Sixteen T2DM patients were subjected to 11 days apart, two isoglycaemic glucose clamp studies in which they compared the pharmacokinetic and pharmacodynamic outcomes of both (150U or 300U) of orally ingested Capsulin and 12U of subcutaneously injected regular human insulin (Actrapid), [77] and Capsulin showed good gastric stability where the dissolution starts in jejunum, reasonable safety profile with well-tolerated statistically significant hypoglycaemia for over 6 h. [75] [76] [77] Another pharmaceutical company, Oramed, has also developed an enteric-coated capsule (ORMD-0801) containing 8 mg insulin which has been marketed for type I and type II diabetic patients. [78, 79] The pharmacokinetic and pharmacodynamic characteristics of ORMD-0801 capsules were evaluated through phase IIa when 2 capsules of the product were given to type 1 diabetic patients. [76] The study concluded the safety and biological activity of the product when given before meals, and it is eliminated in around 5 h. [76] Phase IIb study has been conducted in type 2 patients to also determine how safe, tolerable and effective ORMD-0801 is during 6-week period when compared to placebo. [76] ORMD-0801 showed remarkable reduction in blood glucose level, increased plasma insulin level as well as reduction in C-peptide. [78, 79] A promising approach in oral peptide delivery is the introduction of superporous hydrogel (SPH) and superporous hydrogel composite (SPHC) in targeting proteins to a specific site of the intestine. [80] The new core and shuttle delivery system were developed to mechanically localize the peptide drugs in the intestinal lumen. [80] The drug is incorporated in the core which is either attached to or embedded in the enteric-coated shuttle or conveyor of SPH and SPHC. [80] The novel delivery system tried to achieve an in-vitro double-phase time-controlled release model and showed partial inactivation of trypsin due to calcium binding and enzyme entrapment within the polymeric system. [80] Interpenetrating polymeric networks of superporous hydrogels (SPH-IPNs) using poly (acrylic acid-co-acrylamide) and O-carboxymethyl chitosan have been trialled to estimate insulin transport across rat intestine and colon. [81] No conformational changes to insulin or alterations to its oral bioactivity in terms of hypoglycaemic action have been recorded using (SPH-IPNs) following administration to healthy animals. [81] When it is compared to the subcutaneous route, insulin-loaded SPH-IPNs delivery system achieved around 4% pharmacological availability and the system partly inactivated trypsin and a-chymotrypsin. [81] This system improved paracellular insulin transport through excised rat intestine and across CaCo-2 cell monolayers by 4.2-and 4.9-fold, respectively, via transient opening of epithelial TJs, and it can be retained in rat intestine for longer compared to the powdered SPH-IPN. [82] e Bioadhesive (mucoadhesive) systems and mucus penetrationThe mucoadhesive properties of some polymers have been exploited to prolong the residence time of the drug at its absorption site by increasing the contact with mucosa which in fact increases the concentration gradient of the drug. [83] Some of these polymers in addition to their mucoadhesive characteristics have a dual role as protease inhibitors or permeation enhancers. [83, 84] A new generation of mucoadhesives was formulated via the introduction of thiomers or thiolated polymers. Thiomers have dramatically improved the mucoadhesive properties of anionic polymers such as polyacrylic acid and alginate or cationic polymers such as chitosan. [85] This improvement is attributed to the formation of a stronger disulphide bond which can improve the mucoadhesive properties 140-fold compared to unmodified polymers. [85] Chitosan-4-thiobutylamidine insulin-loaded tablets showed controlled release in non-diabetic rats for over 8 h. [86] Mucus penetration is another technology introduced to overcome the dynamic upstream mucus barrier resulted from its rapid turnover kinetics. [87] [88] [89] Efficient mucus penetration of an insulin carrier requires highly densely charged surface (virus-mimicking strategy), coating of insulin carrier with hydrophilic mucus inert polymer and neutral to slightly negative charged surface (to minimize electrostatic interaction with mucus). [87] PEGylation is one of the approaches that used PEG coat as hydrophilic mucus inert polymer to facilitate mucus penetration of insulin-loaded carriers. [88] Virus-mimicking strategy has been combined with PEGylation technique in a study for oral insulin delivery as a model of utilizing two different concepts for mucus penetration systems. [87] The specific design, PEG molecular weight requirements, limited cellular uptake and induction of anti-PEG antibodies might be considered potential limitations of PEGylation technology.
[88] N-(2-hydroxypropyl) methacrylamide (HPMA) is another hydrophilic mucus inert polymer, and HPMA has been recently used to coat insulin-loaded N-trimethyl chitosan (Ins-TMC) nanocarriers. The novel approach utilized the mucus penetration characteristics of HPMA to deliver the mucoadhesive (Ins-TMC) nanocarriers. Upon oral administration to diabetic rats, remarkable hypoglycaemia has been noticed with a potential success of oral insulin delivery. [89] f Particulate carrier systemFormulation of drugs with colloidal particulate carriers has been widely used to improve peptide delivery. Submicroemulsion, lipid suspension, liposomes, polymeric micro-and nanoparticles and polymeric micelles are good examples of this. [90, 91] These approaches seem to circumvent the existing barriers and harsh gastric conditions for oral peptide delivery demonstrating that good release profiles and the bioactivity of hormones such as insulin could be well maintained too. [90, 91] Encapsulation of insulin in the form of nanospheres facilitates its absorption across the intestinal epithelium. The nanospheres are taken up in tissues such as liver where polymer degradation occurs.
[52] Insulin nanospheres could then function as minor reservoirs for insulin inside the targeted organ (the liver). [52, 64, 92] Chitosan microspheres loaded with insulin have been studied too. Relative increase in insulin pharmacological bioavailability has been observed when optimal particle size of the microspheres is selected. [93] A novel insulin-loaded chitosan phthalate microsphere formulation was found to sustain the plasma glucose of rats for at least 16 h at the prediabetic level with improved oral bioavailability. [94] Another novel solid-in-oil-in-water (S/O/W) emulsion has been formulated with reasonable efficacy in oral delivery of peptides and proteins. This technique is used to encapsulate insulin and showed a pH-responsive release pattern simulating GIT conditions. [95] In an interesting technique based on a low shear reverse micellar approach, a surfactant mixture was prepared by mixing didoceyldimethylammonium bromide (a surfactant) and propylene glycol (a co-surfactant). Triacetin (the oily phase) was then added to the surfactant mixture at the optimized ratio of 1 : 3, respectively. The aqueous insulin solution was eventually added to the previous mixture while stirring to make a final concentration of 20% v/v aqueous phase in the mixture. [96] The transparent microemulsion produced was able to entrap insulin to considerable extent (~85%) without affecting its conformational stability. In-vivo results showed 10-fold improvement in bioavailability compared to plain insulin solution upon oral administration to healthy rats. [96] Limited success since 1976 has been achieved using liposomes for oral delivery of peptides. [97, 98] The unsatisfactory bioavailability with liposomes could be attributed to their instability or limited absorption in GIT conditions, although the natural chemicals (phospholipids) used for formulation are a great advantage. [97, 98] However, a liposomal insulin formulation known as hepatic direct vesicle insulin (HDV-I) has been successfully delivered orally. [55, 99, 100] The novel vesicles are composed of (˂150 nm diameter) liposomes which contain insulin attached to a specific proprietary molecule known as hepatocyte-targeting molecule in an attempt to replicate normal insulin physiology. [55, 99, 100] HDV-I is formulated as an oral gel capsule, stable at low pH of blood and resists gastric degradation with high biopotency.
The solid lipid nanoparticle (SLN) is another example of lipid-based nanoparticulate carrier that has been developed as an alternative to polymeric nanoparticle systems. [101, 102] SLNs show good biocompatibility, biodegradation, sustained release of the incorporated molecules and amenability to large-scale production. [101, 102] Insulin-loaded PEG-stearate-coated lipid nanoparticles offer good protection of the encapsulated insulin when in contact with gastrointestinal fluids compared to non-coated lipid nanoparticles. [103] Self-nanoemulsifying drug delivery systems (SNEDDS) are recent techniques which combine the advantages of nanotechnology and lipid-based drug delivery. [104] The strategy was introduced to improve the formulation of not only the lipophilic drugs but poorly water-soluble therapeutics as well. [104] SNEDDS were initially introduced to overcome the drug solubilization and bioavailability issues of biomolecules due to their ability to enhance droplet surface area, protect from gastric enzymes, improve permeation, alter gastric retention time and sometimes drug mucoadhesive properties. [104] Current applications of SNEDDS include improving drug stability, controlling the drug release, increasing drug loading capacity (<25 mg to >2 g) and specific tissue targeting which can be of potential in lymphoma, leukaemia and autoimmune diseases. [104, 105] In a formulation development study, SNEDDS was produced using a solid dispersion technique in a trial to formulate a non-invasive delivery carrier for therapeutic proteins and it showed promising results. [106] In an attempt to improve oral insulin bioavailability, researchers combined the technology of a multifunctional polymeric system using thiolated chitosan and SNEDDS technology to produce (80-160 nm) spheres with remarkable insulin entrapment efficiency. [107] In-vitro release profile from insulin/ thiolated chitosan SNEDDS significantly increased and serum insulin level showed pronounced increase in in-vivo studies when compared to oral insulin solution. [107] SNEDDS loaded with insulin-lecithin complex facilitated the transport of insulin phospholipid complex across Madin-Darby canine kidney (MDCK) cell monolayer, with no cytotoxicity. [108] Oral administration to diabetic Wistar rats resulted in remarkable hypoglycaemia with relative bioavailability up to 7.15%. [108] In a recent study, a novel SNEDDS was developed to facilitate the mucus permeation of oral insulin, [109] based upon hydrophobic ion pair of insulin with dimyristoyl phosphatidylglycerol (DMPG) to form insulin/DMPG complexes. [104, 109] The technique relied on the fact that insulin acquires net positive charge at low pH which facilitates its conjugation with anionic amphiphilic partners (phospholipids, surfactants and fatty acids) through ionic complexation. [104, 109] In addition to the good permeation characteristic, insulin/ DMPG complex-loaded SNEDDS provided protection from GIT enzymes and prevented initial burst release of insulin which demonstrates a potential for oral insulin delivery. [104, 109] Nanoparticle architecture and polymer choice in oral insulin delivery Nanotechnology using polymers has been one of the most interesting approaches in formulation of peptide therapeutics, and to this end, insulin formulated using nanoparticle technology showed increased cellular uptake and transport across Caco-2 cells. [110] It has been the focus of many researchers to optimize nanoparticle carriers to protect macromolecules from gastric enzymes as well as improve intestinal permeation. [56] Different studies have been carried out using polymer-based nanoparticles for oral insulin delivery using different polymers and their derivatives, and the results have been quite promising [111] (Table 2) . Generally, an ideal polymeric carrier should be biodegradable, biocompatible and able to prolong intestinal residence time after resisting gastric pH gradient and enzymes. [112] Based on nature, polymers utilized in fabrication of insulin nanoparticles are either of natural or synthetic origin. [111, 112] Gelatin and casein, examples of natural protein polymers, have been used to prepare insulin-loaded nanoparticles for per-oral delivery with promising results and good safety profile. [112] Natural polysaccharide polymers have also been used extensively in nanoparticle design of insulin carriers due to their non-toxic characteristics. Examples of these polysaccharides are chitosan, alginate, dextran, starch and pectin. [112] The use of synthetic polymers in formulation of oral insulin has been advantageous in sustaining the release of insulin over a period of days to several weeks compared to natural polymers. [111] Examples of these synthetic polymers are polylactic acid, polylactic co-glycolic acid and poly (Ԑ-caprolactone), and they all have hydrophobic nature. [111, 113] The internalization and uptake process of nanoparticles via the transcellular pathway is dependent on different factors such as surface charge, mucoadhesive properties and particle size. [114, 115] Due to their biocompatibility and low toxicity, gold nanoparticles have been used to deliver insulin orally and intranasally. Hypoglycaemia has been recorded when given to diabetic Wistar rats. [7, 116] Cytotoxicity test as well as immunological response could be a requirement to assess the safety of nanoparticles. Biodegraded nanoparticles if accumulating inside the cells can cause intercellular changes in terms of organelle integrity which could lead to severe toxicity. [117] It has been suggested to consider the nanomaterial waste as unsafe due to their behaviour at the cellular and subcellular levels. [118] Inadequate data about the potential toxicity of nanomaterials to cellular and subcellular organelles are the main reason for the limited use of many nanoparticles. [119] The surface of nanoparticles exhibits high reactivity towards proteins, biomolecules and biological fluids in the cell interior which cause these subcellular structures to associate with the nanoparticle surface in a phenomenon called bimolecular corona formation. [120] The design, chemical composition, size, shape, solubility, surface functionality and aggregation state of nanoparticles are all important factors in controlling and determining not only the cellular and subcellular transport of nanoparticles but their biokinetics and their biodistribution as well. [118, 120, 121] Postinternalization of nanoparticles inside the cells, their surface charge can potentially determine the targeted subcellular organelle (lysosomes, cytoplasm, mitochondria or even the nucleus). [120, 122] Possible cellular toxicity of NPs is best explained through the reactive oxygen species and oxidative stress model [120, 123] which creates a vicious environment such as perturbation of mitochondrial activity, induction of pro-inflammatory effects and nuclear uptake. [118, 121, 123] All these effects could eventually lead to [118, 121, 123] (Figure 4 ). This perturbed activity caused by NPs has been labelled by some scientists as latent toxicity due to modulation of otherwise normal cellular activity. [119] Recent developments in oral insulin delivery A novel intestinal insulin device has been developed from a mixture of mucoadhesive polymers in the form of 13-mm disc. The disc has been coated three times with ethyl cellulose leaving one surface uncoated to ensure unidirectional release of its insulin load. The mucoadhesive disc along with dimethyl palmitoyl ammonio propanesulfonate (a permeation enhancer) has been placed in a capsule (enteric coated with Eudragit L100) for intestinal delivery. After it has been liberated from the capsule shell, the insulin-loaded device completely released its protein content within 4 h with promising results in the animal model. [124] The same technique has been exploited in the development of 500 lm-sized intestinal insulin patch. The novel micropatch (either coated or uncoated) has been encapsulated the same way with dimethyl palmitoyl ammonio propanesulfonate in addition to citric acid (a non-specific protease inhibitor). The small size of the patches delivered in the enteric-coated capsule offered mucoadhesion to larger surface area of the intestinal mucosa and resulted in a significant hypoglycaemia to male Wistar rats following oral administration. [125] In a proof-of-concept study, insulin-loaded dodecylamine-graft-ɣ-polyglutamic acid micelles were developed and cross-linked with trimethyl chitosan (TMC) in the form of nanoparticle complex. The novel self-assembled polyelectrolyte complex nanoparticles are further modified to improve their affinity to the epithelium. This has been achieved by attachment of goblet cell targeting peptide (CSKSSDYQC) to TMC coat. Oral administration of the developed targeted nanoparticles has a relative bioavailability of 7.05% with prolonged hypoglycaemia in diabetic rats. [126] In a novel attempt to modify the hydrophobic nature of SLNs and improve insulin encapsulation efficiency, methocel, a hydrophilic polymer has been incorporated into the internal phase of w/o/w double emulsion based SLN.
Methocel-lipid hybrid nanocarrier (MLN) has been prepared by emulsification solvent evaporation technique. In addition to the improved encapsulation efficiency, MLN also offered extra stability to entrapped insulin with the potential for a promising nanocarrier for oral peptide delivery. In a recent study, polyelectrolyte complexation of two natural polymers chitosan and carboxymethylated iotacarrageenan has been employed in the production of insulin-loaded nanoparticles. The carboxymethylation of iota-carrageenan as well as nanoparticle formulation has been optimized through the computational model, response surface methodology based on Box-Behnken design. Insulin has pH-responsive release from chitosan/carboxymethylated iota-carrageenan nanoparticles with good protection against gastric conditions. [128] Due to the growing interest in developing starch-based nanocarriers, short-chain glucan, SCG (a debranched starch), has been employed in manufacture of insulin-SCG nanoparticles. The addition of cross-linker, proanthocyanidins (PAC) (isolated from red peanut skins) improved the insulin encapsulation efficiency. Insulin SCG/PAC nanoparticles exhibited gastric stability and significant hypoglycaemia for 8 h following oral administration in diabetic rat model. [129] In a proof-of-concept study, insulin-loaded selenium nanoparticles were formulated by ionic cross-linking reduction technique. Insulin-selenium nanoparticles were produced in situ. Addition of sodium selenite and glutathione onto insulin/chitosan complex caused reduction in selenium ion and precipitation of selenium onto insulin/chitosan complex. The produced selenium nanoparticles have good insulin encapsulation efficiency as well as gastric stability. Oral administration of the developed nanoparticles showed remarkable hypoglycaemia in diabetic and nondiabetic rats. The study suggests that selenium can potentiate the antidiabetic effect of insulin and serve as a new oral nanocarrier for the hormone. The study also concluded that insulin-loaded selenium nanoparticles could have the potential to alleviate diabetes-associated oxidative stress and improve pancreatic b-cell functions. [130] In a recent study based on core-shell nanoparticle technology, insulin has been encapsulated in polyurethanealginate core with an outermost shell of chitosan. Insulinloaded polyurethane-alginate/chitosan nanoparticles controlled the release of the entrapped hormone and the mucoadhesive nature played an important role in the hypoglycaemic effect noticed on fasted Swiss albino mice. The histopathological studies suggest the safe use of the developed nanoparticles to deliver insulin orally. [131] In a recent study, hydrophobic ion pairing technology has been employed to complex insulin with sodium deoxycholate. Insulin-sodium deoxycholate complex improved the liposolubility of insulin and enhanced encapsulation efficiency of insulin complex in poly(lactide-co-glycolide) (PLGA). Insulin-loaded PLGA nanoparticles were prepared by emulsion solvent diffusion method. PLGA nanoparticles are then spray-dried with hydroxypropyl methyl cellulose phthalate (a pH-responsive polymer) for intestinal delivery. The new multifunctional composite microcapsule represents a promising carrier for oral peptide delivery. [132] Insulin, insulin-like growth factor (IGF-1) and their receptors Insulin, to mediate its pharmacological effects, has to bind to insulin receptor (IR). [133] IR belongs to a class of receptors known as tyrosine kinase superfamily which comprises IR as well as insulin-like growth factor-1 receptor (IGF-1R). [134] IR and IGF-1R show significant structure homology, and their configurations are almost identical. [134] [135] [136] Figure 5 Simplified diagram of insulin and insulin-like growth factor-1 (IGF-1) signalling pathways. In summary, both are critical to cell health and survival, and there is significant overlap between the two. PI3K, phosphatidyl inositol 3 kinase, Akt; PkB, protein kinase B; Ras, rat sarcoma protein; MAPK, mitogen-activated protein kinase. [Colour figure can be viewed at wileyonlinelibrary.com] IR and IGF-1R are located on the cell surface, and both exhibit heterotetrameric architecture. [134] [135] [136] Each receptor is composed of two extracellular ligand binding a-subunits and two transmembrane b-subunits linked by disulphide bonds. [134] [135] [136] Another hybrid receptor has been identified (IR/IGF-1R) which is composed of one a-subunit and one b-subunit from IR which heterodimerize with similar complementary units from IGF-1R. [134] IR/IGF-1R, the hybrid receptor, exhibits higher affinity towards IGF-1 than insulin and tends to mediate IGF-1 mitogenic responses. [134] Insulin-like growth factors (IGF-1 and IGF-2) are polypeptide ligands that share fundamental structure homology with pro-insulin, and their primary function is to stimulate cell growth, cell differentiation, cell proliferation and cell survival. [133] GIT, liver and other tissues of the body synthesize and secrete IGF-1 and IGF-2, and interestingly, the GIT itself is considered as potential target organ of their mitogenic actions. [136] The close propinquity between insulin and IGF-1 as possible ligands and IR and IGF-1 receptor enables insulin and IGF-1 to bind to each other's receptor and not only to their cognate receptors. [135] Insulin can potentially bind to IGF-1R as well as IGF-2R with much lower affinity. On the other hand, IGF-1 is able to bind to both IGF-1R and IGF2R and weekly to IR. However, IGF-2 can only bind to its receptor and IGF-1R with no affinity towards the IR. [133] IR predominantly serves in expressing the metabolic intracellular pathways while IGF-1R primarily initiates cell growth. [134] It has been reported that some mitogenic effects have been mediated through the IR, whereas IGF-1 has contributed somewhat to this. [136] The growth-promoting effect of insulin on cell proliferation and differentiation has been shown to be dose-dependent. [134, 137] Human IGF-1, on the other hand, increased the sensitization to insulin and has improved fasting and postprandial glycaemia in some clinical studies on type 2 diabetic patients. [134] So, the ligand binding (either insulin or IGF-1) to IR or IGF-1R would potentially activate trans-autophosphorylation and the same downstream signalling pathways for cell proliferation, cell differentiation, anti-apoptotic effect as well as metabolism. [134, 135] Activation of either IR or IGF-1 receptor triggers a series of signalling transduction cascade pathways which can generally be categorized into: A Rat sarcoma protein (Ras)/mitogen-activated protein kinase (MAPK) pathway which significantly mediates mitogenic action and gene expression [133, 138] or B Phosphatidyl inositol 3 kinase (PI3K)/protein kinase B (Akt), a pathway that broadly mediates insulin metabolic effects (glucose homeostasis) in addition to cell migration and anti-apoptotic action [133, 138, 139] (Figure 5 ).
Insulin binding to IR has been reported to stimulate colon cancer cells through the PI3K/Akt pathway. [139] Regardless of insulin type or origin, a potential mechanism of insulin mitogenicity has been explained in a condition of hyperinsulinaemia associated with insulin resistance. [140] This unique effect of insulin is mediated through IR and not thorough IGF-1 receptor. [140] This mechanism is mediated via activation of farnesyltransferase and increases the membrane-anchored farnesylated Ras for further activation by insulin as well as other growth factors. [140] Another possible, yet indirect mitogenic effect of insulin could be achieved by the stimulatory effect of insulin on pituitary gland to produce growth hormone which directly governs IGF-1 production by liver. [133, 136] Longterm use of oral insulin for a chronic disease is still questionable, and being a growth promoter, oral administration of insulin has the potential for inducing mitogenic changes in the gut mucosa which has raised concerns in some scientists. [66, 113] 
Conclusion
Non-invasive hormone and peptide administration has been an interesting challenge for a long time in the pharmaceutical drug delivery field. The limited administration routes and low oral bioavailability of insulin have attracted many scientists since 1922 to tackle and improve more physiological and non-invasive insulin delivery options such as buccal, nasal and ocular delivery routes. Oral delivery of pharmaceuticals especially hormones is of higher preference among all other administration routes. The convenience of administration by patients themselves is a major factor for consideration. In line with this, physicians and clinical diabetologists favour the oral route in diabetes treatment to ensure patient compliance and to achieve the therapeutic targets.
There is a vast body of information in the literature outlining different techniques and strategies to improve oral insulin bioavailability, including proof-of-concept studies indicating the potential feasibility of successful oral insulin administration. The initial promising results obtained from these studies have been an impetus to undergo phase I and II clinical trials of some oral insulin products. The introduction of some innovative approaches such as mucoadhesive polymers, absorption enhancers, protease inhibitors as well as particulate carrier systems has boosted the scope of research in delivering insulin orally by counteracting the naturally existing hurdles and harsh conditions of the GIT. Funding, on the other hand, has always been a paramount limitation to obtain thorough pharmacokinetic and pharmacodynamic data in animals and humans and possible long-term side-effects of the newly introduced oral insulin candidates.
